- Home
- SRRK
as 08-29-2025 2:34pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 3.2B | IPO Year: | 2018 |
| Target Price: | $44.29 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.76 - $46.98 | Next Earning Date: | 08-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 3116.02% |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Parlavecchio Caryn | SRRK | CHRO | Aug 18 '25 | Sell | $31.17 | 2,178 | $67,880.20 | 155,464 | |
| FLIER JEFFREY S. | SRRK | Director | Jun 23 '25 | Sell | $32.70 | 31,452 | $1,024,721.98 | 24,070 | |
| Parlavecchio Caryn | SRRK | CHRO | Jun 16 '25 | Sell | $32.00 | 6,186 | $197,960.66 | 155,464 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Jun 16 '25 | Sell | $32.00 | 7,442 | $238,154.42 | 222,569 | |
| Peng Katie | SRRK | Director | Jun 16 '25 | Sell | $32.24 | 3,031 | $96,888.38 | 34,974 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Insider Monkey
10 days ago
Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD
Simply Wall St.
10 days ago
A Closer Look at Scholar Rock (SRRK) Valuation Following Landmark Phase 3 Data and FDA Priority Review
Business Wire
2 months ago
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
Reuters
2 months ago
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
Insider Monkey
2 months ago
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial
Motley Fool
2 months ago
Why Scholar Rock Shares Are Soaring Today
Investopedia
2 months ago
Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results
MT Newswires
2 months ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.